StockNews.AI

XOMA Royalty Announces CFO Transition

StockNews.AI • 1 minute

OBSICGEMALXN
High Materiality7/10

Information

EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nas...

Original source

AI Summary

XOMA Royalty's CFO Thomas Burns is stepping down, replaced by Jeffrey Trigilio. With a strong financial foundation established, the leadership transition aims to continue driving the royalty aggregator's growth in the biotech sector, capitalizing on its portfolio's future economic potential.

Sentiment Rationale

Leadership changes can create uncertainty; however, the financial stability built by Burns may balance this. Similar transitions in companies can lead to temporary volatility but ultimately maintain or enhance value when experienced leaders are appointed.

Trading Thesis

Consider buying XOMA for potential growth in the biotech royalty sector over the next 6-12 months.

Market-Moving

  • CFO transition may influence investor confidence and stock performance.
  • Leadership continuity may stabilize operations and strategy execution.
  • Performance of portfolio assets could drive future revenue and royalty streams.
  • Market reactions to the new CFO's strategic focus might affect price.

Key Facts

  • CFO Thomas Burns steps down for new opportunities.
  • Jeffrey Trigilio appointed as new CFO with biotech experience.
  • XOMA Royalty established as a key player in biotech royalties.
  • Strong financial foundation set by Burns for future growth.
  • Future economic potential tied to multiple commercial assets.

Companies Mentioned

  • Obsidian Therapeutics (OBSI): Trigilio's past role may lend experience to XOMA.
  • Cullinan Therapeutics (CGEM): Trigilio's experience here could bolster XOMA's strategic outlook.
  • Alexion Pharmaceuticals (ALXN): Background at Alexion may provide relevant industry insights for XOMA.

Corporate Developments

This article fits 'Corporate Developments' as it involves leadership changes that could impact operational strategy and investor sentiment in XOMA's growth prospects.

XOMA Royalty Announces CFO Transition

EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) has officially announced the resignation of Chief Financial Officer Thomas Burns. Mr. Burns will be stepping down from his role to pursue other professional opportunities, marking a significant leadership transition for the company.

Leadership Transition and Acknowledgments

Owen Hughes, Chief Executive Officer of XOMA Royalty, expressed deep gratitude for Mr. Burns’s contributions, stating, “Tom’s leadership, guidance, and resourcefulness have been invaluable as the Company transitioned to and established itself as a royalty aggregator.” He further noted that Mr. Burns's commitment over nearly two decades has built a strong financial foundation to support XOMA Royalty’s future growth.

Reflecting on his tenure, Mr. Burns indicated, “It has been a great honor to have played a key role in the XOMA Royalty journey. With multiple commercial assets and a robust portfolio, XOMA Royalty is firmly established in the biotech royalty segment of the healthcare ecosystem.”

New CFO Appointment: Jeffrey Trigilio

In light of this transition, XOMA Royalty has appointed Jeffrey Trigilio as the new Chief Financial Officer. Mr. Trigilio brings a wealth of experience from various financial, strategic, and business development roles within the biotech industry. He most recently served as Chief Financial and Operating Officer at Obsidian Therapeutics, and previously held the position of Chief Financial Officer at Cullinan Therapeutics.

Mr. Trigilio began his career at Alexion Pharmaceuticals, where he held several key roles in corporate strategy and finance.

In a statement regarding his new position, Mr. Trigilio emphasized the XOMA Royalty leadership team's proven track record: “Together we will continue to execute a strategy of disciplined capital deployment, robust diligence, and innovative deal structuring to enhance our royalty portfolio and generate value for shareholders.”

About XOMA Royalty Corporation

XOMA Royalty Corporation operates as a biotechnology royalty aggregator, focused on supporting biotech companies in their quest to improve human health. By acquiring future economic rights associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical firms, XOMA Royalty provides non-dilutive funding to sellers. This funding enables sellers to advance their drug candidates or utilize it for general corporate purposes.

Currently, XOMA Royalty boasts an extensive and growing portfolio of assets, which are defined as rights to receive future economic benefits linked to the development of therapeutic candidates.

Forward-Looking Statements

Certain statements in this announcement are forward-looking and may involve risks and uncertainties. These statements reflect XOMA Royalty’s beliefs and assumptions as of the date of this release and should not be regarded as guarantees of future performance. Factors that may affect actual results include the ongoing development of product candidates and the viability of the market for these therapeutics.

Investors and interested parties are encouraged to review XOMA Royalty’s filings with the Securities and Exchange Commission for a more detailed discussion of these risks and other factors that could impact results.

Contact Information

Related News